---
title: "APTARGROUP, INC. SEC 10-K Report"
date: "2025-02-08 02:18:01"
summary: "AptarGroup, Inc., a global leader in drug and consumer product dispensing technologies, has released its annual Form 10-K report, showcasing a year of robust financial growth and strategic advancements. The report highlights significant achievements across its business segments, strategic initiatives aimed at enhancing market presence, and a comprehensive overview of..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

AptarGroup, Inc., a global leader in drug and consumer product dispensing technologies, has released its annual Form 10-K report, showcasing a year of robust financial growth and strategic advancements. The report highlights significant achievements across its business segments, strategic initiatives aimed at enhancing market presence, and a comprehensive overview of the challenges and risks faced by the company.

**Financial Highlights**

* **Net Sales**: $3,582.9 million, reflecting a 3% increase from the previous year driven by favorable product mix and volume growth.
* **Operating Income**: $496.5 million, representing a 23% increase due to strong sales growth in the Pharma segment and improved cost management.
* **Net Income**: $374.2 million, a 32% increase attributed to higher sales and improved operational performance.
* **Net Income Attributable to AptarGroup, Inc. per Common Share - Basic**: $5.65, showing significant growth from the prior year.
* **Net Income Attributable to AptarGroup, Inc. per Common Share - Diluted**: $5.53, indicating a 30% growth in diluted earnings per share.

**Business Highlights**

* **Revenue Segments**: Aptar operates through three main segments: Aptar Pharma, Aptar Beauty, and Aptar Closures. Aptar Pharma is the largest segment, representing 46% of net sales, with strong growth in prescription drug delivery systems. Aptar Beauty accounts for 34% of net sales, focusing on pumps and valves for beauty and personal care markets. Aptar Closures, representing 20% of net sales, focuses on dispensing closures for food, beverage, and personal care markets.
* **Geographical Performance**: Europe is the largest region for Aptar, accounting for 49% of sales, with significant exports to North America, Asia, and Latin America. Sales in Asia and Latin America combined represent 19% of consolidated sales, indicating a strong international presence.
* **New Product Launches**: Aptar has introduced several innovative products, including the first fully recyclable pharmaceutical nasal spray and digital health solutions covering a wide range of therapeutic areas.
* **New Production Launches**: The company has expanded its manufacturing capabilities with clean-room facilities in multiple countries, including Argentina, China, France, Germany, India, Switzerland, and the United States, to support its pharmaceutical segment.
* **Future Outlook**: Aptar aims to enhance its position as a global leader in drug and consumer product dispensing technologies by focusing on organic growth, talent acquisition, and strategic acquisitions. The company is committed to sustainability and innovation, with plans to increase its offerings in digital health and sustainable packaging solutions.

**Strategic Initiatives**

* **Restructuring and Cost Optimization**: AptarGroup has focused on optimizing its cost structure through restructuring initiatives, reducing restructuring costs from $45 million in 2023 to $13 million in 2024.
* **Acquisitions and Investments**: The company has invested in acquisitions, such as iD SCENT and Gulf Closures, to expand its market presence and product offerings. A significant equity investment of $99.1 million in Goldrain was made to strengthen strategic partnerships.
* **Capital Management**: AptarGroup reduced its total debt from $1.14 billion in 2023 to $1.03 billion in 2024, improving its Net Debt to Net Capital ratio from 28.3% to 24.4%. The company also repurchased 433,000 shares of its common stock in 2024 and increased its annual dividend for the 31st consecutive year, paying out $114.1 million in dividends.
* **Future Outlook**: AptarGroup plans to continue its focus on strategic investments and capital management to support growth and shareholder value. The company expects to invest between $280 million and $300 million in capital expenditures in 2025 to support its growth strategy, including new manufacturing facilities. AptarGroup aims to maintain its strong financial position by managing its leverage and liquidity, with a consolidated leverage ratio well below the maximum covenant requirement.

**Challenges and Risks**

* **Operational Risks**: Aptar faces significant operational risks due to its reliance on single-source suppliers for certain materials, particularly in its pharmaceutical segment. This dependency could adversely impact the company's ability to deliver products if there are disruptions in supply.
* **Geopolitical Risks**: The company is exposed to geopolitical risks, such as trade disputes and acts of war, which could disrupt operations and affect financial results.
* **Economic Uncertainties**: Economic uncertainties, such as inflation and rising interest rates, could lead to decreased consumer spending and affect customer orders.
* **Cybersecurity Threats**: Cybersecurity threats are a growing concern, with potential risks to data integrity and operational disruptions.
* **Labor and Regulatory Risks**: Labor cost inflation and employee retention challenges could disrupt business operations. The company also faces strong global competition and regulatory risks, including compliance with environmental laws and potential changes in healthcare cost containment policies that could affect pharmaceutical sales.
* **Market Risks**: Aptar is exposed to market risks related to foreign currency exchange rate fluctuations, which could adversely affect financial results. The company uses forward exchange contracts to hedge against these risks, but there is no guarantee of their effectiveness.
* **Tax and Climate Change Risks**: Changes in tax rates and new tax legislation could impact the company's financial condition. The company is also monitoring risks related to climate change and potential regulatory measures that could affect its operations and supply chain.

SEC Filing: [APTARGROUP, INC. [ ATR ] - 10-K - Feb. 07, 2025](https://www.sec.gov/Archives/edgar/data/896622/000089662225000007/atr-20241231.htm)

[TradingView](https://www.tradingview.com/news/tradingview:3be1bf7607e8a:0-aptargroup-inc-sec-10-k-report/)
